Physician profile
Steven Eugene Young
NPI 1093715369
$2,670.45
in general payments reported to CMS, 2019-2025
50 companies · $534 in 2025
The $534 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.89 · 2020: $105 · 2021: $11.39 · 2022: $359 · 2023: $783 · 2024: $782 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.21 |
| Education | $196.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $289.98 | 2023-2025 | Trodelvy |
| Daiichi Sankyo INC. | $212.60 | 2021-2025 | Enhertu |
| Glaxosmithkline, LLC. | $185.04 | 2024-2025 | Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $129.30 | 2023-2025 | Opdivo, Krazati |
| Blueprint Medicines Corporation | $125.34 | 2023-2025 | Ayvakit |
| Epizyme, INC. | $125.00 | 2022 | |
| Karyopharm Therapeutics INC. | $124.99 | 2023 | Xpovio |
| Amgen INC. | $104.29 | 2019-2022 | |
| Janssen Biotech, INC. | $97.87 | 2020-2024 | Talvey, Tecvayli, Darzalex |
| Pfizer INC. | $94.72 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $81.28 | 2019-2025 | |
| Genentech USA, INC. | $73.13 | 2023-2025 | Polivy, Lunsumio, Columvi |
| Astrazeneca Pharmaceuticals Lp | $57.39 | 2023-2025 | Tagrisso |
| Abbvie INC. | $57.04 | 2023-2025 | Venclexta |
| Ipsen Biopharmaceuticals, INC | $53.16 | 2023-2025 | Onivyde, Somatuline Depot |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.